Literature DB >> 20146005

Clinical significance of miR-221 and its inverse correlation with p27Kip¹ in hepatocellular carcinoma.

Xinhui Fu1, Qian Wang, Jingsong Chen, Xiaohui Huang, Xilin Chen, Liangqi Cao, Haoxiang Tan, Wen Li, Longjuan Zhang, Jiong Bi, Qiao Su, Lianzhou Chen.   

Abstract

The aim of the present study is to explore possible role of miR-221 in the pathogenesis of HCC. Matched HCC and adjacent non-cancerous samples were assayed for the expression of miR-221 and three G1/S transition inhibitors: p27(Kip1), p21(WAF1/Cip1)and TGF-β1 by in situ hybridization and immunohistochemistry respectively. p27(Kip1) is one of miR-221's proven targets. Real time qRT-PCR was used to investigate miR-221 and p27(Kip1) transcripts in different clinical stages. Western blotting was used to analyze the expression levels of p27(Kip1) protein in different clinical stages. In result, miR-221 and TGF-β1 are frequently up-regulated in HCC, while p27(Kip1) and p21(WAF1/Cip1) proteins are frequently down-regulated. Moreover, miR-221 and p27(Kip1)'s expression correlated with metastasis and miR-221's expression also correlated with tumor size. Both of p21(WAF1/Cip1)and TGF-β1's expression correlated with tumor differentiations. miR-221's upregulation and p27(Kip1)'s downregulation were significantly associated with tumor stages and metastasis. In conclusion, miR-221 is important in tumorigenesis of HCC, possibly by specifically down-regulating p27(Kip1), a cell-cycle inhibitor. These results indicate miR-221 as a new therapeutic target in HCC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20146005     DOI: 10.1007/s11033-010-9969-5

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  18 in total

1.  Combinatorial microRNA target predictions.

Authors:  Azra Krek; Dominic Grün; Matthew N Poy; Rachel Wolf; Lauren Rosenberg; Eric J Epstein; Philip MacMenamin; Isabelle da Piedade; Kristin C Gunsalus; Markus Stoffel; Nikolaus Rajewsky
Journal:  Nat Genet       Date:  2005-04-03       Impact factor: 38.330

2.  Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.

Authors:  Vassilis G Gorgoulis; Leandros-Vassilios F Vassiliou; Panagiotis Karakaidos; Panayotis Zacharatos; Athanassios Kotsinas; Triantafillos Liloglou; Monica Venere; Richard A Ditullio; Nikolaos G Kastrinakis; Brynn Levy; Dimitris Kletsas; Akihiro Yoneta; Meenhard Herlyn; Christos Kittas; Thanos D Halazonetis
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

3.  MicroRNA expression profiles classify human cancers.

Authors:  Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

4.  Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis.

Authors:  Yoshihiro Edamoto; Akira Hara; Wojciech Biernat; Luigi Terracciano; Gieri Cathomas; Hans-Martin Riehle; Masanori Matsuda; Hideki Fujii; Jean-Yves Scoazec; Hiroko Ohgaki
Journal:  Int J Cancer       Date:  2003-09-01       Impact factor: 7.396

5.  MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma.

Authors:  F Fornari; L Gramantieri; M Ferracin; A Veronese; S Sabbioni; G A Calin; G L Grazi; C Giovannini; C M Croce; L Bolondi; M Negrini
Journal:  Oncogene       Date:  2008-06-02       Impact factor: 9.867

Review 6.  Hepatocellular carcinoma: epidemiology and clinical aspects.

Authors:  Roberto Mazzanti; Laura Gramantieri; Luigi Bolondi
Journal:  Mol Aspects Med       Date:  2007-10-24

7.  MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle.

Authors:  Rosa Visone; Lucia Russo; Pierlorenzo Pallante; Ivana De Martino; Angelo Ferraro; Vincenza Leone; Eleonora Borbone; Fabio Petrocca; Hansjuerg Alder; Carlo Maria Croce; Alfredo Fusco
Journal:  Endocr Relat Cancer       Date:  2007-09       Impact factor: 5.678

8.  Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9.

Authors:  Jing-Song Chen; Qian Wang; Xin-Hui Fu; Xiao-Hui Huang; Xi-Lin Chen; Liang-Qi Cao; Lian-Zhou Chen; Hao-Xiang Tan; Wen Li; Jiong Bi; Long-Juan Zhang
Journal:  Hepatol Res       Date:  2009-02       Impact factor: 4.288

9.  Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated.

Authors:  Xiao-Hui Huang; Qian Wang; Jing-Song Chen; Xin-Hui Fu; Xi-Lin Chen; Lian-Zhou Chen; Wen Li; Jiong Bi; Long-Juan Zhang; Qian Fu; Wen-Tao Zeng; Liang-Qi Cao; Hao-Xiang Tan; Qiao Su
Journal:  Hepatol Res       Date:  2009-03-25       Impact factor: 4.288

Review 10.  Pre-cancerous lesions for colorectal cancers in rodents: a new concept.

Authors:  Yasuhiro Yamada; Hideki Mori
Journal:  Carcinogenesis       Date:  2003-03-28       Impact factor: 4.944

View more
  39 in total

1.  MiR-222 overexpression promotes proliferation of human hepatocellular carcinoma HepG2 cells by downregulating p27.

Authors:  Yue-Feng Yang; Fei Wang; Jun-Jie Xiao; Yang Song; Ying-Ying Zhao; Yan Cao; Yi-Hua Bei; Chang-Qing Yang
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  A meta-analysis of the relationship between glutathione S-transferases gene polymorphism and hepatocellular carcinoma in Asian population.

Authors:  Jie Chen; Liang Ma; Ning-Fu Peng; Shi-Jun Wang; Le-Qun Li
Journal:  Mol Biol Rep       Date:  2012-10-10       Impact factor: 2.316

Review 3.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

4.  Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221.

Authors:  Ying Li; Mei Liu; Yanjun Zhang; Chun Han; Junhao You; Junlan Yang; Cheng Cao; Shunchang Jiao
Journal:  Tumour Biol       Date:  2013-06-26

5.  MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.

Authors:  Juan Du; LiNa Wang; ChenXi Li; HuiLun Yang; YuanBo Li; Haiyang Hu; Hui Li; ZongFeng Zhang
Journal:  Tumour Biol       Date:  2015-10-19

Review 6.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

7.  MicroRNA-221/222 regulate ox-LDL-induced endothelial apoptosis via Ets-1/p21 inhibition.

Authors:  Bing Qin; Yuze Cao; Huan Yang; Bo Xiao; Zhengqi Lu
Journal:  Mol Cell Biochem       Date:  2015-04-17       Impact factor: 3.396

Review 8.  Guide for diagnosis and treatment of hepatocellular carcinoma.

Authors:  Magdy Hamed Attwa; Shahira Aly El-Etreby
Journal:  World J Hepatol       Date:  2015-06-28

Review 9.  MicroRNAs that affect prostate cancer: emphasis on prostate cancer in African Americans.

Authors:  J Jones; W Grizzle; H Wang; C Yates
Journal:  Biotech Histochem       Date:  2013-08-01       Impact factor: 1.718

10.  miR-221 promotes growth and invasion of hepatocellular carcinoma cells by constitutive activation of NFκB.

Authors:  Zimin Liu; Chenghong Wang; Xuelong Jiao; Shanna Zhao; Xudong Liu; Yun Wang; Jian Zhang
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.